No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Cuts Target Price to $13
Morgan Stanley Maintains Foghorn Therapeutics(FHTX.US) With Hold Rating, Maintains Target Price $9
Foghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug Development
12 Health Care Stocks Moving In Monday's Pre-Market Session
Foghorn Therapeutics Is Maintained at Buy by Jefferies
Foghorn Therapeutics Analyst Ratings